Arlington Partners LLC Trims Stock Holdings in Danaher Co. (NYSE:DHR)

Arlington Partners LLC reduced its position in shares of Danaher Co. (NYSE:DHR) by 3.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 13,880 shares of the conglomerate’s stock after selling 471 shares during the period. Arlington Partners LLC’s holdings in Danaher were worth $3,186,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the company. Quilter Plc grew its position in shares of Danaher by 4.6% during the 4th quarter. Quilter Plc now owns 62,371 shares of the conglomerate’s stock valued at $14,317,000 after purchasing an additional 2,746 shares in the last quarter. Elevate Capital Advisors LLC purchased a new position in shares of Danaher during the 4th quarter valued at $829,000. Angeles Wealth Management LLC grew its position in shares of Danaher by 5.1% during the 4th quarter. Angeles Wealth Management LLC now owns 4,229 shares of the conglomerate’s stock valued at $971,000 after purchasing an additional 204 shares in the last quarter. Newbridge Financial Services Group Inc. purchased a new position in shares of Danaher during the 4th quarter valued at $193,000. Finally, Kestra Private Wealth Services LLC grew its position in shares of Danaher by 11.2% during the 4th quarter. Kestra Private Wealth Services LLC now owns 17,480 shares of the conglomerate’s stock valued at $4,013,000 after purchasing an additional 1,754 shares in the last quarter. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Danaher

In related news, SVP Brian W. Ellis sold 5,700 shares of the business’s stock in a transaction dated Thursday, January 30th. The shares were sold at an average price of $224.13, for a total transaction of $1,277,541.00. Following the transaction, the senior vice president now owns 20,230 shares in the company, valued at $4,534,149.90. The trade was a 21.98 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 11.10% of the stock is owned by corporate insiders.

Danaher Stock Performance

Shares of NYSE:DHR opened at $206.92 on Monday. The company has a market cap of $149.45 billion, a price-to-earnings ratio of 39.19, a price-to-earnings-growth ratio of 2.68 and a beta of 0.83. The company has a 50-day moving average price of $232.72 and a 200-day moving average price of $251.70. The company has a current ratio of 1.40, a quick ratio of 1.05 and a debt-to-equity ratio of 0.31. Danaher Co. has a 12 month low of $205.79 and a 12 month high of $281.70.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Wednesday, January 29th. The conglomerate reported $2.14 EPS for the quarter, meeting the consensus estimate of $2.14. Danaher had a net margin of 16.33% and a return on equity of 10.82%. During the same quarter in the prior year, the business earned $2.09 earnings per share. As a group, equities analysts anticipate that Danaher Co. will post 7.67 EPS for the current year.

Danaher Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, January 31st. Investors of record on Friday, December 27th were given a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a dividend yield of 0.52%. The ex-dividend date of this dividend was Friday, December 27th. Danaher’s dividend payout ratio is currently 20.45%.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on DHR shares. StockNews.com lowered shares of Danaher from a “buy” rating to a “hold” rating in a research report on Saturday, December 14th. Scotiabank began coverage on shares of Danaher in a research report on Monday, December 23rd. They issued a “sector perform” rating and a $265.00 target price for the company. Royal Bank of Canada reiterated an “outperform” rating and issued a $277.00 target price (down from $299.00) on shares of Danaher in a research report on Thursday, January 30th. KeyCorp upped their target price on shares of Danaher from $290.00 to $310.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 23rd. Finally, Barclays cut their target price on shares of Danaher from $275.00 to $240.00 and set an “equal weight” rating for the company in a research report on Thursday, January 30th. Seven investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $278.00.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.